Circulating soluble LOX-1 and patient prognosis after an acute coronary syndrome
Elevated plasma sLOX-1 at baseline and during follow-up is associated with incident HF and MACE, as well as cardiac and coronary dysfunction in patients with ACS. As plasma sLOX-1 levels may reflect the intensity of LOX-1 expression on vascular and immune cells, these findings support LOX-1 as a potentially important therapeutic target to improve prognosis in patients with ACS.
Authors
- Anna Collén (ORCID: https://orcid.org/0000-0002-3220-7247)
- Alexandru Șchiopu (ORCID: https://orcid.org/0000-0002-7587-5050)
- Isabel Gonçalves (ORCID: https://orcid.org/0000-0002-2935-0181)
- Sara Svedlund (ORCID: https://orcid.org/0000-0002-4359-7463)
- Gayathri Narasimhan (ORCID: https://orcid.org/0000-0003-0495-5210)
- Vijayalakshmi Varma
- Emily L. Ongstad (ORCID: https://orcid.org/0000-0002-6980-8433)
- Troels Yndigegn (ORCID: https://orcid.org/0000-0002-8960-2125)
- Li‐Ming Gan (ORCID: https://orcid.org/0000-0003-2933-1404)
- Jan Nilsson
- Bi Juin Loong
Institutions
- Lund University (SE)
- AstraZeneca (Japan) (JP)
- AstraZeneca (Finland) (FI)
- Skåne University Hospital (SE)
- AstraZeneca (Sweden) (SE)
- University of Gothenburg (SE)
Publication Details
- Journal
- Heart
- Published
- 2025-09-16
- DOI
- https://doi.org/10.1136/heartjnl-2025-326315
- Primary Topic
- Atherosclerosis and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00